-
L1023 Anti-Cancer Compound Library for ccRCC
2026-08-16
PLAC1 has emerged as a prognostic biomarker and molecular target in clear cell renal cell carcinoma. This thought-leadership guide shows how researchers can translate that finding into biomarker-aware screening and validation using the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023), while distinguishing mechanistic evidence from actionable workflow recommendations.
-
JSH-23: A Practical NF-κB Inhibitor Workflow
2026-08-15
JSH-23 gives researchers a mechanistically focused way to separate NF-κB p65 nuclear transcription from upstream IκB turnover. This guide translates that distinction into cell-based inflammation assays, cytokine studies, and cautious disease-model validation.
-
MDL 28170: A Selective Calpain Inhibitor
2026-08-14
MDL 28170 combines cell permeability, blood-brain barrier access, and dual calpain/cathepsin B inhibition for mechanistic studies of neuronal injury, apoptosis, and protease-driven cytotoxicity. This guide translates recent hippocampal findings into practical workflows while distinguishing validated evidence from optimization starting points.
-
FPR2/ALX Signaling in Autoimmune Astrocytopathy
2026-08-14
The reference study identifies FPR2/ALX stimulation by Quin-C1 as an immunomodulatory strategy that limits AQP4-IgG- and complement-driven autoimmune astrocytopathy in mice. Its depletion and pathway-inhibition experiments implicate microglia, natural killer cells, and SYK-AKT signaling in the protective response, while also highlighting the need for validation beyond the animal model.
-
Nitrocefin: From β-Lactamase Signal to Translation
2026-08-13
Nitrocefin converts β-lactamase hydrolysis into a rapid yellow-to-red signal, giving translational researchers a practical bridge between enzyme mechanism, resistance profiling, inhibitor discovery, and computational peptide screening. This article outlines how to interpret the assay beyond a simple color change and how to position it within a rigorous development workflow.
-
Decitabine Primes Progenitor Tex for PD-1 Blockade
2026-08-13
A 2023 Journal of Clinical Investigation study shows that low-dose decitabine can improve anti–PD-1 therapy by expanding CD8+ progenitor exhausted T cells rather than merely reactivating terminally exhausted cells. The work identifies sustained JunD and JNK/AP-1 activity as an important mechanistic link and offers a framework for evaluating epigenetic priming in tumor-immunology models.
-
Dextrose Workflows for Hypoxic Tumor Research
2026-08-12
Build controlled hypoxia–nutrient experiments with Dextrose (D-glucose), from fresh stock preparation to immune–tumor co-culture readouts. This workflow emphasizes matched controls, practical concentration matrices, and troubleshooting strategies that distinguish glucose effects from oxygen, osmotic, and handling artifacts.
-
Angiotensin (1-7): Applied Research Workflows
2026-08-12
Build reproducible Mas-receptor, fibrosis, inflammation, metabolic, and peptide–receptor-binding assays around a high-purity endogenous heptapeptide. This guide connects literature-backed benchmarks with practical stock preparation, dose selection, assay controls, and troubleshooting for translational research.
-
Dihydrotestosterone: From AR Trigger to Assay Design
2026-08-11
Dihydrotestosterone (DHT) is a precise androgen receptor perturbation tool for studying transcription, EGFR–ERBB2 signaling, and muscle phenotypes. This guide connects product handling with evidence-based assay decisions and insights from a recent prostate biology study.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-08-11
Sulfo-NHS-LC-Biotin is a water-soluble reagent for stable biotin labeling of accessible primary amines on proteins, peptides, and intact-cell surfaces. It is suited to aqueous cell-surface and protein workflows using biotin-avidin or streptavidin capture, but not to reversible labeling or intracellular labeling of cells with intact plasma membranes.
-
GOB-38 in Elizabethkingia anophelis: Evidence and Methods
2026-08-10
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, by combining genomic analysis, recombinant expression, biochemical profiling, and co-culture experiments. Its findings connect broad β-lactam hydrolysis and an unusual active-site composition with clinically important resistance and the possible exchange of carbapenem resistance during polymicrobial infection.
-
MDockPeP2_VS: Screening Peptide Inhibitors
2026-08-09
Xu and colleagues introduce MDockPeP2_VS, a structure-based peptide-screening strategy that reduces conformational search by using conservation between protein folding and protein–peptide binding. In a TEM-1 β-lactamase demonstration, the workflow identified TF7 as an inhibitory peptide with a reported Ki of 1.37 ± 0.37 μM, providing a practical starting point for peptide-based antibiotic resistance research.
-
MLKL Polymerization and Cathepsin B in Necroptosis
2026-08-08
The reference study identifies lysosomal membrane permeabilization as a decisive intermediate between MLKL polymerization and plasma membrane rupture during necroptosis. Its imaging, perturbation, and MLKL-domain experiments support a model in which lysosomal release of cathepsin B helps execute cell death, creating a defined experimental framework for studying lysosome–protease mechanisms.
-
FAK Inhibitor 14: From EMT Mechanism to Translation
2026-08-07
A translational framework for using FAK Inhibitor 14 to interrogate PARP1/FAK/COL5A1 signaling, EMT, and migration in cholesterol-resistant ovarian cancer models.
-
MDL 28170: Next-Generation Calpain Inhibition for Translatio
2026-08-07
This thought-leadership article examines the mechanistic underpinnings and translational strategies for targeting calpain-mediated pathology, anchored by new evidence linking MDL 28170 to neurodevelopmental protection and cognitive rescue. By integrating breakthrough findings, advanced protocol guidance, and a critical view of the competitive landscape, the article delivers actionable insights for researchers designing high-impact neuroprotection, apoptosis, and ischemia-reperfusion injury models.